FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308134450> ?p ?o ?g. }

• W4308134450 endingPage "A562" @default.
• W4308134450 startingPage "A561" @default.
• W4308134450 abstract "Abstract We have developed a technology platform employing enteric coating and permeation enhancement to enable systemic delivery of peptides via the oral route. To determine whether this platform can deliver therapeutic doses of the GnRH agonist leuprolide, we conducted a randomized, four-period, four-treatment, crossover pharmacokinetic and food effect study in 14 healthy female volunteers, which compared PK profiles following single administrations of 1 and 4 mg of leuprolide --- the latter under both fasting and fed conditions --- to that of a single subcutaneous injection of 1 mg of leuprolide acetate. Study objectives were to assess the relative bioavailability, dose proportionality, safety and tolerability of orally administered leuprolide, as well as the effect of food on drug absorption. Frequent blood sampling for 24 hours followed each dose, and each treatment was separated by 7 days. Of the 14 subjects enrolled and dosed, 12 completed the study. Mean Tmax occurred at 2.24 ±0.38, 2.77 ±0.46, and 3.49 ±0.23 hrs, for 1 mg po, 4 mg po (fasting), and 1 mg sc leuprolide, respectively. Mean Cmax was 1.9 ±1.3, 10.2 ±9.6, and 59.4 ±9.1 ng/mL, for the aforementioned treatments. Mean AUC0-24h was 3.5 ±2.1, 19.3 ±16.8, and 163.0 ±18.8 ng*h/mL, respectively. Relative to 1 mg sc leuprolide, oral doses of 1 mg and 4 mg (fasted) achieved 2.2 ±1.3% and 3.0 ±2.5% bioavailability. While differences in the dose-normalized parameters were not statistically significant, formal criterion of dose-proportionality (i.e. 90% CI within 80-125%) was not met. 'Fasting' conditions included an overnight (10-hr) fast prior to dosing, and no food consumption for 4 hours following dosing. The 'fed' condition involved consumption of a high-fat, high-calorie meal 30 minutes prior to drug administration. Significant negative impact of food on both rapidity and extent of drug absorption was observed in nearly all subjects, with measurable leuprolide levels sufficiently sparse as to prevent robust PK assessments in this group. The subject incidence of treatment-emergent adverse events (TEAEs) was comparable across all four treatment groups, including sc leuprolide, and was not dose-dependent. The most commonly observed TEAEs across all treatment groups combined were nausea (43%), headache (43%), and increased libido (21%). All other TEAEs were reported by only one or two subjects. The study drugs were well tolerated; most AEs were mild in severity (none were severe or serious), and 30 of 53 (57%) deemed unrelated to study drug. No notable changes were observed in laboratory values or vital signs. This study thus confirmed the successful oral delivery of leuprolide, a 1209-dalton nonapeptide, via the oral route. Investigations now in progress are assessing the feasibility of delivering substantially greater amounts of the drug orally, in order to provide an alternative to parenteral administration of this widely used therapeutic. Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m." @default.
• W4308134450 created "2022-11-08" @default.
• W4308134450 creator A5000163946 @default.
• W4308134450 creator A5028560951 @default.
• W4308134450 creator A5058002412 @default.
• W4308134450 creator A5074722777 @default.
• W4308134450 creator A5076831902 @default.
• W4308134450 creator A5082592492 @default.
• W4308134450 creator A5087282265 @default.
• W4308134450 creator A5091445745 @default.
• W4308134450 date "2022-11-01" @default.
• W4308134450 modified "2023-10-18" @default.
• W4308134450 title "PMON70 Systemic Delivery of Leuprolide via Oral Administration" @default.
• W4308134450 doi "https://doi.org/10.1210/jendso/bvac150.1166" @default.
• W4308134450 hasPublicationYear "2022" @default.
• W4308134450 type Work @default.
• W4308134450 citedByCount "0" @default.
• W4308134450 crossrefType "journal-article" @default.
• W4308134450 hasAuthorship W4308134450A5000163946 @default.
• W4308134450 hasAuthorship W4308134450A5028560951 @default.
• W4308134450 hasAuthorship W4308134450A5058002412 @default.
• W4308134450 hasAuthorship W4308134450A5074722777 @default.
• W4308134450 hasAuthorship W4308134450A5076831902 @default.
• W4308134450 hasAuthorship W4308134450A5082592492 @default.
• W4308134450 hasAuthorship W4308134450A5087282265 @default.
• W4308134450 hasAuthorship W4308134450A5091445745 @default.
• W4308134450 hasBestOaLocation W43081344501 @default.
• W4308134450 hasConcept C112705442 @default.
• W4308134450 hasConcept C142724271 @default.
• W4308134450 hasConcept C181389837 @default.
• W4308134450 hasConcept C197934379 @default.
• W4308134450 hasConcept C204787440 @default.
• W4308134450 hasConcept C22979827 @default.
• W4308134450 hasConcept C27081682 @default.
• W4308134450 hasConcept C2777056448 @default.
• W4308134450 hasConcept C2778375690 @default.
• W4308134450 hasConcept C71924100 @default.
• W4308134450 hasConcept C77281830 @default.
• W4308134450 hasConcept C87813604 @default.
• W4308134450 hasConcept C98274493 @default.
• W4308134450 hasConceptScore W4308134450C112705442 @default.
• W4308134450 hasConceptScore W4308134450C142724271 @default.
• W4308134450 hasConceptScore W4308134450C181389837 @default.
• W4308134450 hasConceptScore W4308134450C197934379 @default.
• W4308134450 hasConceptScore W4308134450C204787440 @default.
• W4308134450 hasConceptScore W4308134450C22979827 @default.
• W4308134450 hasConceptScore W4308134450C27081682 @default.
• W4308134450 hasConceptScore W4308134450C2777056448 @default.
• W4308134450 hasConceptScore W4308134450C2778375690 @default.
• W4308134450 hasConceptScore W4308134450C71924100 @default.
• W4308134450 hasConceptScore W4308134450C77281830 @default.
• W4308134450 hasConceptScore W4308134450C87813604 @default.
• W4308134450 hasConceptScore W4308134450C98274493 @default.
• W4308134450 hasIssue "Supplement_1" @default.
• W4308134450 hasLocation W43081344501 @default.
• W4308134450 hasLocation W43081344502 @default.
• W4308134450 hasOpenAccess W4308134450 @default.
• W4308134450 hasPrimaryLocation W43081344501 @default.
• W4308134450 hasRelatedWork W1982777678 @default.
• W4308134450 hasRelatedWork W1984317973 @default.
• W4308134450 hasRelatedWork W1984498366 @default.
• W4308134450 hasRelatedWork W2026309482 @default.
• W4308134450 hasRelatedWork W2068318921 @default.
• W4308134450 hasRelatedWork W2069936009 @default.
• W4308134450 hasRelatedWork W2080955156 @default.
• W4308134450 hasRelatedWork W2151097881 @default.
• W4308134450 hasRelatedWork W2359419803 @default.
• W4308134450 hasRelatedWork W2418409895 @default.
• W4308134450 hasVolume "6" @default.
• W4308134450 isParatext "false" @default.
• W4308134450 isRetracted "false" @default.
• W4308134450 workType "article" @default.